Concord Biotech Limited
CONCORDBIO.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$142.78B
Close$
$179.87
86.6% downside
Current Fair Value
86.6% downsideOvervalued by 86.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $142.78 Billion |
|---|---|
| Enterprise Value | $142.78 Billion |
| Dividend Yield | $7.55 (0.55%) |
| Earnings per Share | $24.78 |
| Beta | 0.35 |
| Outstanding Shares | 104,616,204 |
Return
| Return on Equity | 13.64% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 51.88 |
|---|---|
| PEG | 157.99 |
| Price to Sales | 12.75 |
| Price to Book Ratio | 6.97 |
| Enterprise Value to Revenue | 12.88 |
| Enterprise Value to EBIT | 40.75 |
| Enterprise Value to Net Income | 51 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 31, 2026
EPS Estimate
$7.38
Average shareholder expectationRevenue Estimate
$2.72 B
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$7.03
Average shareholder expectationRevenue Estimate
$2.99 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Concord Biotech Limited
1,624 employees
CEO: Ankur Vaid Established in 1984 and headquartered in Ahmedabad, India, Concord Biotech Limited operates as a biopharmaceutical company engaged in the comprehensive research, development, manufacturing, marketing, and global sales of pharmaceutical p...